Additionally, analysis of clinico-pathological parameters in the TCGA cohort revealed a significantly positive correlation between low DKK3 expression and a negative hormone receptor (ER and PR, both P < 0.001) as well as a negative HER2 status (P < 0.001) and greater tumor size (P < 0.01, S7 Table), underlining an association between loss of DKK3 expression and the aggressive TNBC subgroup [3]. Here, DKK3 is linked to neoplasm.